AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$AGL

Agilon Health Q3 Earnings Call Highlights

Agilon Health (NYSE: AGL) reported a medical services expense ratio of 88.5% in Q3, down from 104% a year earlier. The company exceeded adjusted EBITDA guidance by $64M, citing favorable risk adjustments and cost trends. Agilon raised its full-year cash outlook to at least $175M and expects 40-50% ACO membership growth in 2027. CEO Tim O'Rourke highlighted clinical program expansions and plans for new market partnerships.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 7:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Agilon Health Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AGLBullishMed
01

Why it matters

The earnings beat and raised cash guidance provide a fresh catalyst that could drive the stock higher in the short term.

02

Market read

First disclosure of Q3 financials and forward guidance for Agilon Health, a material update for investors.

03

What to watch

Potential regulatory changes to Medicare Advantage could affect future profitability.

Relevance 7/10Novelty 7/10Timing: after‑hours earnings call

Background

Agilon Health (NYSE:AGL) reported Q3 results, highlighting a lower medical services expense ratio and an EBITDA beat.

Company-level read

Ticker impact

$AGLBullishHigh confidence
Context

Q3 adjusted EBITDA beat guidance by $64M and raised year‑end cash outlook to at least $175M, with higher guidance for 2027 ACO membership.

Expected impact

likely upward pressure as investors price in stronger earnings and higher cash guidance

Evidence & confidence

The company delivered better-than-expected EBITDA, improved expense ratio, and lifted cash outlook, which are material new data for a mid‑cap health‑tech stock.

Market effects

Sector

Improved ACO performance may boost sentiment for value‑based care providers.

Regional

Limited to U.S. healthcare services sector.

Global

Modest; primarily affects U.S. investors in health‑tech stocks.

Counterpoint

What could challenge this read

Higher guidance could be offset by execution risk in scaling ACO membership.

Key entities

  • Executive
    Tim O'Rourke

    CEO of Agilon Health, discussed ACO growth and future guidance.

  • Executive
    Schwaneke

    Provided detailed financial commentary during the earnings call.

Read at source← All news

StoryAgilon Health reports Q3 2026 beat and raises full‑year revenue and EBITDA guidance

Also covered by

2 outlets

Related articles

$AGLMed

Agilon Health Inc (AGL) (Q3 2026) Earnings Call Highlights: Guidance Raised as Adjusted

Agilon Health Inc (AGL) reported Q3 2026 earnings, beating guidance with adjusted EBITDA of $64M, up from -$91M in Q3 2025. The company raised full-year 2026 guidance and expects 40-50% ACO membership growth in 2027. However, Medicare Advantage membership declined 10% YoY, and medical costs remain high. The company plans to expand into new markets starting in 2028. AGL ended Q3 with $312M in cash and raised its year-end cash outlook to at least $175M.

finance.yahoo.com
$AGLHighAI 8/10

Agilon: Q3 Earnings Snapshot

Agilon Health Inc. (AGL) reported Q3 net income of $34.9M, or $1.97 per share, beating analyst expectations of a loss. Revenue was $1.52B, also exceeding forecasts. The company expects full-year revenue between $5.87B and $5.89B. Shares have increased fivefold in the past year, closing at $95.76 on Wednesday.

finance.yahoo.com
$AGLMed

agilon health, inc. (AGL): Revenue increased 6% to $1.52 billion Compared to the Same Period in the Prior Year Increases Full Year 2026 Guidance to Reflect Positive Third Quarter Results

agilon health, inc. (AGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 agilon health Reports Third Quarter 2026 Results Revenue increased 6% to $1.52 billion Compared to the Same Period in the Prior Year Increases Full Year 2026 Guidance to Reflect Positive Third Quarter Results Westerville, O.H., November 4, 2026 – agilon health, inc.

SEC EDGAR 8-K